Synthesis, Anticancer and Antibacterial Activity of Some Novel Mononuclear Ru(II) Complexes
作者:Upal Kanti Mazumder、Malaya Gupta、Subhas Somalingappa Karki、Shiladitya Bhattacharya、Suresh Rathinasamy、Sivakumar Thangavel
DOI:10.1248/cpb.52.178
日期:——
In search of potential anticancer drug candidates in ruthenium complexes, a series of mononuclear ruthenium complexes of the type [Ru(phen)2(nmit)]Cl2 (Ru1), [Ru(bpy)2(nmit)]Cl2 (Ru2), [Ru(phen)2(icpl)]Cl2 (Ru3), Ru(bpy)2(icpl)]Cl2 (Ru4) (phen=1,10-phenanthroline; bpy=2,2′-bipyridine; nmit=N-methyl-isatin-3-thiosemicarbazone, icpl=isatin-3-(4-Cl-phenyl)thiosemicarbazone) and [Ru(phen)2(aze)]Cl2 (Ru5), [Ru(bpy)2(aze)]Cl2 (Ru6) (aze=acetazolamide) and [Ru(phen)2(R-tsc)](ClO4)2 (R=methyl (Ru7), ethyl (Ru8), cyclohexyl (Ru9), 4-Cl-phenyl (10), 4-Br-phenyl (Ru11), and 4-EtO-phenyl (Ru12), tsc=thiosemicarbazone) were prepared and characterized by elemental analysis, FTIR, 1H-NMR and FAB-MS. Effect of these complexes on the growth of a transplantable murine tumor cell line (Ehrlich Ascites Carcinoma) and their antibacterial activity were studied. In cancer study the effect of hematological profile of the tumor hosts have also been studied. In the cancer study, the complexes Ru1—Ru4, Ru10 and Ru11 have remarkably decreased the tumor volume and viable ascitic cell count as indicated by trypan blue dye exclusion test (p<0.05). Treatment with the ruthenium complexes prolonged the lifespan of Ehrlich Ascites Carcinoma (EAC) bearing mice. Tumor inhibition by the ruthenium chelates was followed by improvements in hemoglobin, RBC and WBC values. All the complexes showed antibacterial activity, except Ru5 and Ru6. Thus, the results suggest that these ruthenium complexes have significant antitumor property and antibacterial activity. The results also reflect that the drug does not adversely affect the hematological profiles as compared to that of cisplatin on the host.
为了寻找潜在的抗癌药物候选物,合成并表征了一系列单核钌配合物,包括[Ru(phen)2(nmit)]Cl2 (Ru1)、[Ru(bpy)2(nmit)]Cl2 (Ru2)、[Ru(phen)2(icpl)]Cl2 (Ru3)、[Ru(bpy)2(icpl)]Cl2 (Ru4)(其中phen=1,10-菲咯啉,bpy=2,2'-联吡啶,nmit=N-甲基-异氮茚-3-缩氨基硫脲,icpl=异氮茚-3-(4-氯苯基)缩氨基硫脲),以及[Ru(phen)2(aze)]Cl2 (Ru5)、[Ru(bpy)2(aze)]Cl2 (Ru6)(aze=醋唑磺胺)和[Ru(phen)2(R-tsc)](ClO4)2(R=甲基(Ru7)、乙基(Ru8)、环己基(Ru9)、4-氯苯基(Ru10)、4-溴苯基(Ru11)和4-乙氧基苯基(Ru12),tsc=缩氨基硫脲)。研究了这些配合物对可移植的小鼠肿瘤细胞系(埃利希腹水癌)生长的影响及其抗菌活性。在癌症研究中,还研究了肿瘤宿主血液学特征的影响。在癌症研究中,配合物Ru1—Ru4、Ru10和Ru11显著减少了肿瘤体积和活腹水细胞数量,通过台阶蓝染色排斥试验显示(p<0.05)。使用这些钌配合物治疗延长了携带埃利希腹水癌(EAC)小鼠的寿命。钌配合物抑制肿瘤后,血红蛋白、红细胞和白细胞值有所改善。所有配合物都显示出抗菌活性,除了Ru5和Ru6。因此,结果表明这些钌配合物具有显著的抗肿瘤特性和抗菌活性。结果还反映出,与顺铂相比,该药物对宿主的血液学特征没有负面影响。